KR101739313B1 - 광견병 바이러스를 중화시킬 수 있는 결합 분자 - Google Patents

광견병 바이러스를 중화시킬 수 있는 결합 분자 Download PDF

Info

Publication number
KR101739313B1
KR101739313B1 KR1020140178030A KR20140178030A KR101739313B1 KR 101739313 B1 KR101739313 B1 KR 101739313B1 KR 1020140178030 A KR1020140178030 A KR 1020140178030A KR 20140178030 A KR20140178030 A KR 20140178030A KR 101739313 B1 KR101739313 B1 KR 101739313B1
Authority
KR
South Korea
Prior art keywords
ser
seq
thr
val
binding molecule
Prior art date
Application number
KR1020140178030A
Other languages
English (en)
Korean (ko)
Other versions
KR20150068913A (ko
Inventor
김판겸
김동조
김철민
류수희
맹기은
박인창
서지민
신지영
안정선
장신재
홍승서
Original Assignee
(주)셀트리온
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)셀트리온 filed Critical (주)셀트리온
Publication of KR20150068913A publication Critical patent/KR20150068913A/ko
Application granted granted Critical
Publication of KR101739313B1 publication Critical patent/KR101739313B1/ko

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036Retroviridae, e.g. leukemia viruses
    • C07K16/1045Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020140178030A 2013-12-12 2014-12-11 광견병 바이러스를 중화시킬 수 있는 결합 분자 KR101739313B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020130154731 2013-12-12
KR20130154731 2013-12-12

Publications (2)

Publication Number Publication Date
KR20150068913A KR20150068913A (ko) 2015-06-22
KR101739313B1 true KR101739313B1 (ko) 2017-05-24

Family

ID=53371482

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020140178030A KR101739313B1 (ko) 2013-12-12 2014-12-11 광견병 바이러스를 중화시킬 수 있는 결합 분자

Country Status (3)

Country Link
KR (1) KR101739313B1 (zh)
CN (1) CN105814077B (zh)
WO (1) WO2015088256A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160145508A (ko) * 2015-06-10 2016-12-20 (주)셀트리온 광견병 바이러스 g 단백질의 에피토프 및 이에 특이적으로 결합하는 광견병 바이러스 중화 결합 분자

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109369803B (zh) * 2018-09-07 2021-05-04 深圳市国创纳米抗体技术有限公司 一种抗狂犬病毒g蛋白的纳米抗体及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68920502T2 (de) * 1988-08-01 1995-05-18 Akzo Nobel Nv Pseudorabiesvirus-Impfstoff.
ES2468021T3 (es) * 2004-05-27 2014-06-13 Crucell Holland B.V. Moléculas de unión que pueden neutralizar el virus de la rabia y usos de las mismas
KR101159806B1 (ko) * 2010-02-05 2012-06-27 대한민국 광견병 바이러스를 중화하는 단클론항체 4G31의 scFv유전자 및 이를 발현한 재조합단백질
WO2013048130A2 (ko) * 2011-09-30 2013-04-04 (주)셀트리온 광견병 바이러스를 중화시킬 수 있는 결합 분자

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J Antivir Antiretrovir, Vol 5, Pages 37-43(2013.03.30.)*

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160145508A (ko) * 2015-06-10 2016-12-20 (주)셀트리온 광견병 바이러스 g 단백질의 에피토프 및 이에 특이적으로 결합하는 광견병 바이러스 중화 결합 분자
KR101969626B1 (ko) * 2015-06-10 2019-04-16 (주)셀트리온 광견병 바이러스 g 단백질의 에피토프 및 이에 특이적으로 결합하는 광견병 바이러스 중화 결합 분자
US10722571B2 (en) 2015-06-10 2020-07-28 Celltrion Inc. Rabies virus G protein epitope, and rabies virus neutralising binding molecule that binds specifically thereto

Also Published As

Publication number Publication date
CN105814077B (zh) 2019-07-26
KR20150068913A (ko) 2015-06-22
WO2015088256A1 (ko) 2015-06-18
CN105814077A (zh) 2016-07-27

Similar Documents

Publication Publication Date Title
KR102255099B1 (ko) 2 이상의 인플루엔자 a 바이러스 중화 결합 분자를 포함하는 조성물
RU2755503C2 (ru) Анти-lag-3 антитела и их композиции
CN107206074B (zh) 双特异性四价抗体及其制备和使用方法
KR102275513B1 (ko) 항-ptk7 항체-약물 접합체
CN110214153B (zh) 抗pd-1抗体及组合物
CN109715671B (zh) 双特异性抗her2抗体
TWI628190B (zh) 可結合及中和b型流感病毒之人類結合分子及其用途
KR101969626B1 (ko) 광견병 바이러스 g 단백질의 에피토프 및 이에 특이적으로 결합하는 광견병 바이러스 중화 결합 분자
CN106715471B (zh) 抗cd127的抗体
KR20110102198A (ko) 인간 b 세포에서 생산된 인플루엔자 a 바이러스 중화 활성을 가지는 인간 단일클론 항체
KR20230125859A (ko) 암에 대한 조합 요법
KR101937733B1 (ko) 광견병 감염의 방지 및 치료에 관한 조성물 및 방법
CN113874081A (zh) 高-亲和力抗-mertk抗体及其用途
KR102453573B1 (ko) 항-pacap 항체
CN106795223A (zh) 针对Fcγ受体IIB及Fcε受体的新型抗体
EP3821006A2 (en) Antibodies specific to folate receptor alpha
US20220041749A1 (en) Antibodies specific to muc18
KR101739313B1 (ko) 광견병 바이러스를 중화시킬 수 있는 결합 분자
KR101634636B1 (ko) 개량형 인간화 항-인간 α9 인테그린 항체
CN113135994A (zh) 一种激活型抗ox40抗体、生产方法及应用
CN114685653B (zh) 抗新冠病毒受体结合区域表位中和抗体及其应用
CN114805557B (zh) 人源化抗SARS-CoV-2单克隆抗体及其应用
CN114845738A (zh) 使用位点特异性her2抗体-药物缀合物的治疗
KR20120107050A (ko) 광견병 바이러스를 중화시킬 수 있는 결합 분자

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant